Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer

被引:263
作者
Tokunaga, T
Oshika, Y
Abe, Y
Ozeki, Y
Sadahiro, S
Kijima, H
Tsuchida, T
Yamazaki, H
Ueyama, Y
Tamaoki, N
Nakamura, M [1 ]
机构
[1] Tokai Univ, Sch Med, Dept Pathol, Kanagawa 25911, Japan
[2] Natl Def Med Coll, Dept Surg 2, Tokorozawa, Saitama 356, Japan
[3] Tokai Univ, Sch Med, Dept Surg, Kanagawa 25911, Japan
[4] Kanagawa Acad Sci & Technol, Kanagawa 213, Japan
关键词
vascular endothelial growth factor; isoform pattern; liver metastasis; colon cancer;
D O I
10.1038/bjc.1998.164
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) is a well known factor that induces angiogenesis. Four isoforms, i.e. VEGF206, 189, 165, and 121, have been identified. We examined the isoform patterns of VEGF mRNA using reverse transcription polymerase chain reaction (RT-PCR) analysis in 61 colon cancers. All the colon cancers examined expressed VEGF121. The isoform patterns were classified into three groups: type 1, VEGF121; type 2, VEGF121 + VEGF165; type 3, VEGF121 + VEGF165 + VEGF189. Three of the 61 colon cancers examined showed type 1 expression, 26 showed type 2 expression and 32 showed the type 3 pattern. The patients with liver metastases showed the type 3 isoform expression pattern at a significantly higher incidence (12 of 16, 75%) than those without liver metastasis (20 of 45, 44%) (P = 0.036). The type 3 isoform pattern was significantly associated with M1 stage (P = 0.019). The patients with colon cancer and the type 3 isoform pattern showed significantly poor prognosis (P < 0.01, Cox-Mantel). The colon cancers with the type 3 pattern showed a significantly higher involvement of veins (P = 0.006), These observations suggest that the aberrant type 3 expression pattern of VEGF189 mRNA isoforms is correlated with liver metastasis, M stage, and poor prognosis in colon cancer.
引用
收藏
页码:998 / 1002
页数:5
相关论文
共 22 条
[1]   HIGHER FREQUENCY OF POINT MUTATIONS IN THE C-K-RAS 2 GENE IN HUMAN COLORECTAL ADENOMAS WITH SEVERE ATYPIA THAN IN CARCINOMAS [J].
ANDO, M ;
MARUYAMA, M ;
OTO, M ;
TAKEMURA, K ;
ENDO, M ;
YUASA, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 1991, 82 (03) :245-249
[2]   EXPRESSION OF THE VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR GENE IN CENTRAL-NERVOUS-SYSTEM NEOPLASMS [J].
BERKMAN, RA ;
MERRILL, MJ ;
REINHOLD, WC ;
MONACCI, WT ;
SAXENA, A ;
CLARK, WC ;
ROBERTSON, JT ;
ALI, IU ;
OLDFIELD, EH .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :153-159
[3]   VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) GENE IS EXPRESSED DIFFERENTIALLY IN NORMAL-TISSUES, MACROPHAGES, AND TUMORS [J].
BERSE, B ;
BROWN, LF ;
VANDEWATER, L ;
DVORAK, HF ;
SENGER, DR .
MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (02) :211-220
[4]   EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS FLT AND KDR IN OVARIAN-CARCINOMA [J].
BOOCOCK, CA ;
CHARNOCKJONES, DS ;
SHARKEY, AM ;
MCLAREN, J ;
BARKER, PJ ;
WRIGHT, KA ;
TWENTYMAN, PR ;
SMITH, SK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07) :506-516
[5]   EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER [J].
BROWN, LF ;
BERSE, B ;
JACKMAN, RW ;
TOGNAZZI, K ;
GUIDI, AJ ;
DVORAK, HF ;
SENGER, DR ;
CONNOLLY, JL ;
SCHNITT, SJ .
HUMAN PATHOLOGY, 1995, 26 (01) :86-91
[6]  
BROWN LF, 1993, CANCER RES, V53, P4727
[7]   VEGF(121), A VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) ISOFORM LACKING HEPARIN-BINDING ABILITY, REQUIRES CELL-SURFACE HEPARAN SULFATES FOR EFFICIENT BINDING TO THE VEGF RECEPTORS OF HUMAN-MELANOMA CELLS [J].
COHEN, T ;
GITAYGOREN, H ;
SHARON, R ;
SHIBUYA, M ;
HALABAN, R ;
LEVI, BZ ;
NEUFELD, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (19) :11322-11326
[8]   EFFECTS OF A VARIETY OF CYTOKINES AND INDUCING AGENTS ON VASCULAR-PERMEABILITY FACTOR MESSENGER-RNA LEVELS IN U937 CELLS [J].
DOLECKI, GJ ;
CONNOLLY, DT .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 180 (02) :572-578
[9]  
DVORAK HF, 1995, AM J PATHOL, V146, P1029
[10]   PLATELET FACTOR-IV INHIBITS THE MITOGENIC ACTIVITY OF VEGF(121) AND VEGF(165) USING SEVERAL CONCURRENT MECHANISMS [J].
GENGRINOVITCH, S ;
GREENBERG, SM ;
COHEN, T ;
GITAYGOREN, H ;
ROCKWELL, P ;
MAIONE, TE ;
LEVI, BZ ;
NEUFELD, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (25) :15059-15065